




RealRate

PHARMACEUTICAL 2025

Inmed Pharmaceuticals Inc
Rank 69 of 225



The relative strengths and weaknesses of Inmed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Inmed Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 87% points. The greatest weakness of Inmed Pharmaceuticals Inc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 283%, being 68% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	8,690
Cost of Goods Sold	3,497
Intangible Assets	1,783
Liabilities, Current	1,972
Liabilities, Non-Current	645
Other Assets	100
Other Compr. Net Income	0
Other Expenses	289
Other Liabilities	0
Other Net Income	528
Other Revenues	4,598
Property and Equipment	1,250
Research and Development	3,218
Selling, General and Administrative Expense	5,798

Output Variable	Value in 1000 USD
Assets	11,823
Liabilities	2,617
Expenses	12,801
Revenues	4,598
Stockholders Equity	9,206
Net Income	-7,676
Comprehensive Net Income	-7,676
BaseVar	16,183
ECR before Limited Liability	172%
Economic Capital Ratio	283%